Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 18, 2024 3:26pm
126 Views
Post# 36318541

Yes, Bucky you are the smartest person ever!

Yes, Bucky you are the smartest person ever!

That's right Bucky, I sure you have both a medical degree & a business degree.
How elese could one qualify to openly trash the analysts?
Then again, my quick resurch. You have posted hundreds of comments. Consistently FUD.
and, in the language of about a grade 4, maybe grade 5 throwing insults on the playground..
I encourage you to read ( or if too many bi* words ), have someone explain the pedigree the anakysts bring to the table.
Repeating myself, they all use a measurement called Present value of future income.
look it up on Wikipedia.
They all more or less say the same thing.
Assuming Onc gets Pela to market there will be xxx $$ , income / year.
Then they use industry accepted calculations to determine what thst income would relate to , for corporate value.
Then they apply a " risk discount factor".
obviouly the further out , the greater the risk factor.
They are legally bound by their professions & various governing entities, to provide back up for their recommendations, pricie targets etc.
Some of the analysts , also add in industry comparables.
Thst being what notable has done, with many of his posts.
bucky in the other hand, childish one line FUD.
Ussually misquoting or somewhat  misleading statements..
Bucky , since you know so much , please pick up the phone & let the listed collaborators know what yiu know.
list if collaborations with Onc;
pfizer
roche ( 5 Gobblet arms, one advancing to enabling trial, others could follow)
incyte ( 3- MBc)
PanCan, they set up the orriginal Pancreatic cancer, next phase trial, through precision promise. Sadly they were under funded by congress & cancelld all future trials....yet they still million grant to Onc, to add the additional panc cancer arm.
CGAR, took over from PanCan & are now the lead with upcoming pancreatic cancer trial with Onc/ Roche 
I could go on, as there are more.
My point, these institutions ALL did massive due diligence prior to entering into agreements with oncolytics biotech.
The analysts know that, those of us who can read, know that.
Obviously you know more than they do, please give them a call.

 

<< Previous
Bullboard Posts
Next >>